Replies to post #63987 on Savvy Trades and Investments

[value1008]

ACST - the extra commentary with lots of details about the Phase 3 trial sounded positive; 68% of patients already treated, and no delay of results expected. Mkt likes to hear that... Amazing that it recovered so much on such a big down day for biotechs and markets in general.